 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Research Articles |
OBJECTIVE: To identify patient-specific factors predictive of maintenance warfarin dosage requirements >5 mg/d. METHODS: One hundred forty-six adults taking warfarin were identified from a community hospital and an outpatient anticoagulation clinic. Patient demographics and data on warfarin doses, laboratory results, and medication use were obtained by abstracting patient records. Estimates of vitamin K intake were obtained using a questionnaire and structured interview. Multiple logistic regression was used to identify patient characteristics independently predictive of warfarin maintenance requirements >5 mg/d. An assessment tool for estimating an individual patient's likelihood of requiring warfarin maintenance doses >5 mg/d was derived from the logistic regression model and was assessed in both the study cohort and a separate historical validation cohort of 125 patients. RESULTS: Five factors were independently associated with warfarin requirements >5 mg/d: age <55 years, male gender, African American ethnicity, vitamin K intake >400 micro g/d, and body weight >or=91 kg. The assessment tool derived from these factors correctly classified semiquantitative warfarin requirements as non-high-dose in 84 of 93 study cohort patients and 71 of 78 validation cohort patients, and correctly classified requirements as high-dose in 10 of 13 study cohort patients and 11 of 15 validation cohort patients. CONCLUSIONS: African American ethnicity is a newly identified predictor of warfarin requirements >5 mg/d and is independent of dietary vitamin K intake. An assessment tool incorporating this and other predictors can estimate a patient's likelihood of requiring such dosages.
This article has been cited by other articles:
|
|
 |
|
  E. Aklillu, C. Leong, R. Loebstein, H. Halkin, and E. Gak VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals Blood, April 1, 2008; 111(7): 3903 - 3904. [Full Text] [PDF]
|
|
|
|
|
|
R. Loebstein, I. Dvoskin, H. Halkin, M. Vecsler, A. Lubetsky, G. Rechavi, N. Amariglio, Y. Cohen, G. Ken-Dror, S. Almog, et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance Blood, March 15, 2007; 109(6): 2477 - 2480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kubitza, M. Becka, M. Zuehlsdorf, and W. Mueck Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59-7939) in Healthy Subjects J. Clin. Pharmacol., February 1, 2007; 47(2): 218 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J McGriff-Lee, G. Csako, J. T Chen, D. K Dang, K. G Rosenfeld, R. O Cannon, L R. Macklin, R. A Wesley, and Anticoagulation Working Group Search for Predictors of Nontherapeutic INR Results with Warfarin Therapy Ann. Pharmacother., December 1, 2005; 39(12): 1996 - 2002. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Rieder, A. P. Reiner, B. F. Gage, D. A. Nickerson, C. S. Eby, H. L. McLeod, D. K. Blough, K. E. Thummel, D. L. Veenstra, and A. E. Rettie Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose N. Engl. J. Med., June 2, 2005; 352(22): 2285 - 2293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-T. N Dang, J. Hambleton, and S. R Kayser The Influence of Ethnicity on Warfarin Dosage Requirement Ann. Pharmacother., June 1, 2005; 39(6): 1008 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D Eckhoff, R. J DiDomenico, and N. L Shapiro Initiating Warfarin Therapy: 5 mg versus 10 mg Ann. Pharmacother., December 1, 2004; 38(12): 2115 - 2121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kurnik, A. Lubetsky, R. Loebstein, S. Almog, and H. Halkin Multivitamin Supplements May Affect Warfarin Anticoagulation in Susceptible Patients Ann. Pharmacother., November 1, 2003; 37(11): 1603 - 1606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D Lindh Comment: patient-specific factors predictive of warfarin dosage requirements Ann. Pharmacother., March 1, 2003; 37(3): 454 - 454. [Full Text] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
